Coenzyme Q10 in Older Athletes Treated With Statin Medications

R

Richard Deichmann, MD

Status and phase

Completed
Phase 4

Conditions

Myalgia
Side Effects of Statins
Muscle Weakness

Treatments

Drug: Coenzyme q 10
Drug: placebo

Study type

Interventional

Funder types

Other

Identifiers

NCT01026311
09-076

Details and patient eligibility

About

The purpose of this study is to evaluate the effect of coenzyme Q10 administration in improving mitochondrial function as measured by anaerobic threshold in older athletes on a stable dose of statin medication.

Enrollment

20 patients

Sex

All

Ages

50+ years old

Volunteers

Accepts Healthy Volunteers

Inclusion criteria

  • Patients ≥ 50 years of age, male or female.
  • Patients on a stable dose of statin medication for at least 3 months prior to enrollment in the study

Self-Described Athletes with any of the following characteristics:

  • Participation in a competitive athletic event within the past year or currently training for a competitive athletic event within the 6 months following enrollment
  • Regular exercise activity of at least 45 minutes duration 5 times per week

Exclusion criteria

  • Use of coenzyme Q10 during the preceding two months.
  • CPK level at baseline greater than two times the upper limits of normal
  • LDL level at baseline greater than 160 for those without a cardiovascular risk or cardiovascular risk equivalent
  • LDL level at baseline greater than 130 for those with a cardiovascular risk or cardiovascular risk equivalent

Trial design

Primary purpose

Treatment

Allocation

Randomized

Interventional model

Crossover Assignment

Masking

Double Blind

20 participants in 2 patient groups, including a placebo group

placebo
Placebo Comparator group
Treatment:
Drug: placebo
Coenzyme Q10
Active Comparator group
Description:
200mg of coenzyme Q10
Treatment:
Drug: Coenzyme q 10

Trial contacts and locations

1

Loading...

Data sourced from clinicaltrials.gov

Clinical trials

Find clinical trialsTrials by location
© Copyright 2024 Veeva Systems